menu
    • menu
    [{"orgOrder":0,"company":"BioGenCell","sponsor":"Marius Nacht","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"BGC101","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"BioGenCell \/ Marius Nacht","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Marius Nacht"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"BGC101","moa":"","graph1":null,"graph2":null,"graph3":"BioGenCell","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"BioGenCell \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioGenCell \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BioGenCell

    Menu

    BioGenCell

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioGenCell

                            Israel arrow
                            Cosmoprof
                            Not Confirmed

                            BioGenCell

                            Israel arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BGC101

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioGenCell Receives FDA Fast Track Designation with Expanded Access for BGC101

                            Details : BGC101 leverages BioGenCell's proprietary TRACT platform to develop personalized stem cell therapies. It is being evaluated for the treatment of chronic limb-threatening ischemia.

                            Brand Name : BGC101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 19, 2024

                            Lead Product(s) : BGC101

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioGenCell

                            Israel arrow
                            Cosmoprof
                            Not Confirmed

                            BioGenCell

                            Israel arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BGC101

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Marius Nacht

                            Deal Size : $16.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BioGenCell, Developer of A Unique Platform for Treating Microvascular Disease, Has Completed a $16 Million See...

                            Details : Financing will support BioGenCell's innovative, accessible and painless medical platform focuses on BGC101 and pipeline. The product BGC101, treats severe limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers.

                            Brand Name : BGC101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 09, 2022

                            Lead Product(s) : BGC101

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Marius Nacht

                            Deal Size : $16.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth